Company intelligence / Profile preview
Seurat Therapeutics
Chicago, Illinois, United Statespitchbook.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Developing an Insulin-like-growth factor-1 (IGF-1) nasal spray formulation that can relieve migraines within 30 minutes by targeting the root cause rather than alleviating symptoms. The therapy mimics the anti-migraine effects of environmental enrichment by reducing brain inflammation and the local concentration of inflammatory cytokines[1][7].
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Cytokine therapy (IGF-1 nasal spray formulation)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Chicago
Beyond the preview
Go deeper on Seurat Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seurat Therapeutics.